More about NATCO Pharma Limited
Fundamentals for NATCO Pharma Limited
Regulatory Filings for NATCO Pharma Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Technicals for NATCO Pharma Limited
Price Summary
NATCO Pharma Limited's shares increased 3.36% today, reflecting a outstanding day on the market.On 2026-03-02, NATCO Pharma Limited's stock opened at 925.15, reached 967.85, hit a low of 925.15, and rose 3.36% to close at 956.25, with 1073075 shares traded.
The stock reached its highest price of 1035.1 and its lowest price of 746.5 during the 52-week period.
11 analysts estimate that the future price of NATCOPHARM will fall between 712.0 and 1480.0, with an average price expectation of approximately 970.36365.
Technicals
Aroon: The current reading of the AROON is neutral, offering no clear signals for a movement in either direction. This suggests that the market may be in a holding pattern, with no dominant trend in place.
Bol. Bands: The BOLL BANDS is in a neutral stance for NATCOPHARM, not indicating a clear upward or downward trend. This suggests a period of market indecision, where neither bulls nor bears have the upper hand.
Parabolic SAR: The PSAR remains bullish, establishing a key support level that could help uphold the market's upward trajectory. This persistent bullish outlook suggests that the market may continue to rise, with the support providing a foundation for further gains.
Stochastic: The K-line has dropped below the D-line on the stochastic indicator while staying above 80, suggesting that a bearish price move may be beginning. This pattern indicates that the market's upward momentum is weakening, potentially leading to a reversal. Investors should stay alert for additional signs of a downturn.
Tripple Moving Agerage: The 20, 50, and 100 moving averages are currently aligned in a bearish pattern, indicating a downtrend. However, the slopes of the 20 and 50 SMAs are showing signs of wavering, suggesting that the bearish momentum for NATCOPHARM may be fading. This could signal a potential shift towards bullish price action, as the market's downward trajectory begins to lose strength and prepares for a possible reversal.
A thorough analysis of a company involves looking at both its fundamentals and technical data. The fundamentals, including revenue, profitability, and management quality, offer insight into the company's long-term value. Additionally, understanding the broader industry context, such as market competition and regulatory challenges, helps to better interpret the company's stock performance. By combining both fundamental and technical analysis, you can derive more meaningful inferences about the company's future prospects.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction